SS
GTBP icon

SBI Securities’s GT Biopharma GTBP Stock Holding History

SBI Securities’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Hold
0
– – – 4130
2026
Q1 		– Hold
0
– – – 4084
2025
Q4 		– Hold
0
– – – 3997
2025
Q3 		– Hold
0
– – – 4132
2025
Q2 		– Hold
0
– – – 3908
2025
Q1 		– Sell
-1
Closed -$59 – 3886
2024
Q4 		$49 Buy
+1
New +$68 ﹤0.01% 3648

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

SBI Securities's GTBP Position: Q2 2026 in Review

SBI Securities held its GT Biopharma (GTBP) position steady in Q2 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4130.

SBI Securities first reported a position in GTBP in Q4 2024 and has held it in 1 quarter since. The position peaked at $49 in Q4 2024. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • SBI Securities held 0 shares of GT Biopharma worth $0 as of Q2 2026.
  • SBI Securities left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #4130 holding.
  • SBI Securities first reported a position in GT Biopharma in Q4 2024 and has held it in 1 quarter since.
  • SBI Securities's GT Biopharma position peaked at $49 in Q4 2024.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.